@FiercePharma: Stats, surprises and secrets revealed in annual drug-spending report. Story | Follow @FiercePharma
@EricPFierce: #FDA finds sends a warning letter to a second Novacyl API plant for retesting failed batches. News | Follow @EricPFierce
@CarlyHFierce: UPDATED: Just where does AbbVie expect to find $7B in Imbruvica sales? Article | Follow @CarlyHFierce
> Actavis ($ACT) and Allergan ($AGN) shareholders approved the companies' plans to merge, clearing the way for the $66 billion deal to close this quarter or early next. Release
> Cost-effectiveness watchdogs in England backed Roche's ($RHHBY) new leukemia drug, Gazyvaro, for use by the National Health Service. Report
> Jordan-based Hikma Pharmaceuticals posted a 9% hike in 2014 revenue, but said it expects growth at 6% for this year. Report
> The family of a Propecia user who committed suicide sued Merck ($MRK), alleging that the company failed to warn about the drug's potential to increase the risk of suicidal thoughts and behavior. Report
> The Danish biotech Bavarian Nordic said its U.S. smallpox vaccine sales fueled its first full-year profit in 5 years. Report
Medical Device News
@FierceMedDev: J&J hosts developer of novel skin cancer diagnostic at its new life science incubator. FierceDiagnostics article | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Texas Medical Center adds 20+ device companies to its incubator. Story | Follow @VarunSaxena2
@EmilyWFierce: Get this week's edition of FierceDiagnostics, feat. OpGen's superbug Dx, new coverage decisions for $EXAS and more. Newsletter | Follow @EmilyWFierce
> Med tech moves in on Georgia: Varian, MiMedix to expand with up to 250 new jobs. Story
> J&J's DePuy Synthes recalls orthopedic surgical tool, but not ready to replace. News
> Olympus asked FDA to loosen its belt on cleaning guidelines for endoscope devices. Article
Biotech News
@FierceBiotech: From @FiercePharmAsia: Glaxo plants a flag in Singapore with CEO Witty on hand. More | Follow @FierceBiotech
@JohnCFierce: ICYMI: Amgen is canning 300 Onyx staffers, abandoning campus in latest biopharma purge. News | Follow @JohnCFierce
@DamianFierce: $PTX is buying the rights to $ZGNX's opioid Zohydro ER for $100M up front and up to $283.5M more. Release | FiercePharma story | Follow @DamianFierce
> The Fierce survey: Is this a biotech bubble or a sustainable bull market? More
> Glaxo plants a flag in Singapore with CEO Witty on hand. Item
> Intrexon partner AmpliPhi raises $13M for antibiotic R&D. News
Drug Delivery News
> Zohydro changes hands as Zogenix sells to Pernix for $100M-plus. More
> J&J partner Halozyme joins daratumumab trials with delivery tech in tow. Story
> Irish research center wins EU funding to study and develop transdermal delivery methods. News
> Will the third licensee of a buccal tablet for mouth fungus succeed where others have failed? More
> Developer of injectable osteoarthritis treatment postpones $75M IPO, raises $4M in debt instead. Article
Diagnostics News
> Philips, UC Irvine collaborate on diagnosing breast cancer among women with dense breasts. Story
> Exact Sciences signs on Anthem and Aetna to noninvasive colon cancer Dx. Report
> Quest and Personalis dive into exome sequencing for rare pediatric neurological disorders. Editor's corner
> J&J hosts developer of novel skin cancer diagnostic at its new life science incubator in Silicon Valley. More
> Navidea joins forces with Norgine to market cancer imaging Dx in EU. Article
Pharma Marketing News
> Lipitor keeps on selling, so Pfizer will keep on producing it in Ireland. Item
> Just where does AbbVie expect to find $7B in Imbruvica sales? Story
> Stats, surprises and secrets revealed in annual drug-spending report. More
> Onyx field reps spared in Amgen's 300-job bloodletting. Article
> Bayer puts cancer-fighting country crooner onstage to promote colonoscopies. Report
And Finally... The activist group Public Citizen is leading a charge against an FDA proposal to allow drugmakers to distribute peer-reviewed journal articles that may contradict a drug's official safety labeling. Report